Spencer Kobren speaks with IAHRS accepted member and current ISHRS President, Jerry Cooley M.D. about ACell MatriStem, a product that some are saying is the most groundbreaking development in the fight against hair loss since the FDA approval of Propecia.
Hair Loss in women is a silent epidemic of tremendous proportions. More than forty percent of hair loss sufferers in the U.S are women and a large percentage of these women are between the ages of 18 to 35.
As disturbing as male pattern baldness is for men, for women, hair loss can be downright devastating.
AOL’s StyleList takes a closer look at this growing epidemic.
Histogen to present one year clinical trial data at Society for Investigative Dermatology Annual Meeting
SAN DIEGO, April 13, 2010 – Histogen, Inc., a regenerative medicine company developing solutions based on the products of newborn cells grown under embryonic conditions, today announced the one year data findings of its Hair Stimulating Complex (HSC) pilot clinical trial. Statistically significant new hair growth was seen in HSC-treated subjects at this follow-up timepoint, one year after their single treatment with HSC.
The Food & Drug Administration said Tuesday that it will be taking steps to regulate the three most potent forms of medical radiation. With that, it will require that manufacturers of certain CT scanning equipment redesign machines to incorporate safeguards aimed at reducing patients’ exposure to radiation.
The decision comes on the heels of several recent alarming reports of accidental overdoses of radiation from miscalibrated CT scanning machines.
Scientists from from Colombia, Rockefeller and Stanford Universities, believe they have discovered a gene that significantly impacts hair growth as well as hair follicle miniaturization; the phenomenon that is the cornerstone of male and female pattern baldness.